ADSTILADRIN

STN: BLA 125700
Proper Name: nadofaragene firadenovec-vncg
Tradename: ADSTILADRIN
Manufacturer: Ferring Pharmaceuticals A/S
Indication: 

• High-grade, Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer

Product Information

• Package Insert - ADSTILADRIN

Supporting Documents

• March 23, 2026 Approval Letter - ADSTILADRIN
• October 9, 2025 Approval Letter - ADSTILADRIN
• August 5, 2024 Approval Letter - ADSTILADRIN
• May 1, 2024 Approval Letter - ADSTILADRIN
• December 16, 2022 Approval Letter - ADSTILADRIN
• December 16, 2022 Summary Basis for Regulatory Action - ADSTILADRIN
• Approval History, Letters, Reviews and Related Documents - ADSTILADRIN